Contribuição da densidade do PSA para predizer o câncer da próstata em pacientes com valores de PSA entre 2,6 e 10,0 ng/ml

• Autor(a) principal: Castro, Hugo Alexandre Sócrates de [UNIFESP]
• Data de Publicação: 2011
• Outros Autores: Iared, Wagner [UNIFESP], Shigueoka, David Carlos [UNIFESP], Mourão, José Eduardo [UNIFESP], Ajzen, Sergio Aron [UNIFESP]
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/S0100-39842011000400003; http://repositorio.unifesp.br/handle/11600/6542
• topic: Prostate; Prostate biopsy; Prostate cancer; PSA density; Próstata; Biópsia de próstata; Câncer de próstata; Densidade de PSA

OBJECTIVE: To study the profile of patients with PSA level between 2.6 and 10.0 ng/ml and submitted to prostate biopsy, determining possible patterns that might lead to a reduction of unnecessary biopsies. MATERIALS AND METHODS: In the period from 2007 to 2009, a cross-sectional study was developed with 1,282 patients with PSA levels between 2.6 and 10.0 ng/ml, and submitted to prostate biopsy. RESULTS: Cancer prevalence was 28.6%. On average, the patients with positive biopsies were older, with higher PSA levels and density, and smaller prostate volume as compared with the patients with negative biopsies. In the analysis of PSA density, the cancer patients averaged 0.31 ng/ml/cc, while patients with negative results averaged 0.10 ng/ml/cc. Utilizing a cutoff value of 0.15 ng/ml/cc for PSA density as a cancer positiveness criterion, the authors obtained sensitivity of 74% and specificity of 70%. The cutoff value should be reduced to increase the sensitivity. With a cutoff value of 0.09 ng/ml/cc, sensitivity reached 84% (CI 95%: 80-87%), and specificity, 75% (CI 95%: 72-78%). CONCLUSION: The systematic use of PSA density as an indicator to proceed with the investigation of a patient with biopsy could substantially reduce the amount of unnecessary procedures.